公开(公告)号：EP0719556B1

公开(公告)日：2000-10-25

申请号：EP95120021.1

申请日：1995-12-19

申请人： SANWA KAGAKU KENKYUSHO CO., LTD.

发明人： Sawai, Kiichi, c/o Sanwa Kagaku Kenkyusho Co., Ltd ,  Ban, Masatoshi, c/o Sanwa Kagaku Kenkyusho Co, Ltd ,  Sato,Makoto, c/o Sanwa Kagaku Kenkyusho Co, Ltd ,  Hibi, Chihiro, c/o Sanwa Kagaku Kenkyusho Co, Ltd ,  Mizuno, Kuniharu, c/o Sanwa Kagaku Kenkyusho Co.

IPC分类号： A61K31/415

CPC分类号： A61K31/4188

公开(公告)号：EP0719556A3

公开(公告)日：1997-02-26

申请号：EP95120021.1

申请日：1995-12-19

申请人： SANWA KAGAKU KENKYUSHO CO., LTD.

发明人： Sawai, Kiichi, c/o Sanwa Kagaku Kenkyusho Co., Ltd ,  Ban, Masatoshi, c/o Sanwa Kagaku Kenkyusho Co, Ltd ,  Sato,Makoto, c/o Sanwa Kagaku Kenkyusho Co, Ltd ,  Hibi, Chihiro, c/o Sanwa Kagaku Kenkyusho Co, Ltd ,  Mizuno, Kuniharu, c/o Sanwa Kagaku Kenkyusho Co.

IPC分类号： A61K31/415

CPC分类号： A61K31/4188

摘要： An agent for treating diabetic keratopathy which comprises (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamide as an active ingredient. It is in the form of, in particular, oral preparations or eye drops and composed of a composition which is efficacious against diabetic corneal epitheliopathy, diabetic corneal imperception and diabetic corneal endotheliopathy. The mechanism of diabetic keratopathy occurrence has not been clarified and thus no effective remedy therefor has been developed so far. It is a disease accompanied by various abnormalities in the corneal epithelium, perception (Schwann cells) and endothelial cells. When the cornea undergoes severe disintegration, vesicular keratopathy occurs and seriously damages the visual function. Thus it frequently becomes intractable. The present invention provides an efficacious treating agent for this disease.

公开(公告)号：EP0719556A2

公开(公告)日：1996-07-03

申请号：EP95120021.1

申请日：1995-12-19

申请人： SANWA KAGAKU KENKYUSHO CO., LTD.

发明人： Sawai, Kiichi, c/o Sanwa Kagaku Kenkyusho Co., Ltd ,  Ban, Masatoshi, c/o Sanwa Kagaku Kenkyusho Co, Ltd ,  Sato,Makoto, c/o Sanwa Kagaku Kenkyusho Co, Ltd ,  Hibi, Chihiro, c/o Sanwa Kagaku Kenkyusho Co, Ltd ,  Mizuno, Kuniharu, c/o Sanwa Kagaku Kenkyusho Co.

IPC分类号： A61K31/415

CPC分类号： A61K31/4188

摘要： An agent for treating diabetic keratopathy which comprises (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamide as an active ingredient. It is in the form of, in particular, oral preparations or eye drops and composed of a composition which is efficacious against diabetic corneal epitheliopathy, diabetic corneal imperception and diabetic corneal endotheliopathy. The mechanism of diabetic keratopathy occurrence has not been clarified and thus no effective remedy therefor has been developed so far. It is a disease accompanied by various abnormalities in the corneal epithelium, perception (Schwann cells) and endothelial cells. When the cornea undergoes severe disintegration, vesicular keratopathy occurs and seriously damages the visual function. Thus it frequently becomes intractable. The present invention provides an efficacious treating agent for this disease.

摘要翻译： 一种治疗糖尿病性角膜病的药剂，其特征在于，含有（2S，4S）-6-氟-2'，5'-二氧代环苯并噻喃-4,4'-咪唑啉-2-甲酰胺作为活性成分。 其特别是口服制剂或滴眼剂的形式，并且由对糖尿病性角膜上皮病，糖尿病角膜缺陷和糖尿病性角膜内皮细胞病变有效的组合物组成。 糖尿病性角膜病的发生机制尚未得到澄清，迄今尚未形成有效的治疗方法。 它是伴随着角膜上皮，感知（雪旺氏细胞）和内皮细胞的各种异常的疾病。 当角膜发生严重的分解时，发生囊泡性角膜病，严重损害视力。 因此，它经常变得棘手。 本发明提供了用于该疾病的有效治疗剂。